⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Fig.S9 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers

Wei Zhou Peng Fang Dongan Yu Hongyuan Ren Meng You Long Yin Fei Mei Huikai Zhu Zhenzhen Wang Hui Xu Yuxia Cao Xiaowei Sun Xiaohong Xu Jianjun Bi Jin Wang Lanping Ma Xin Wang Lin Chen Yongliang Zhang Xiaowei Cen Xi Zhu Liguang Lou Datao Liu Xiaoding Tan Jinliang Yang Tao Meng Jingkang Shen

View at Publisher

Ask AI

Bookmark

Share

Abstract

Affinity of 9MW2821 and enfortumab vedotin (EV) to recombinant human Fcγ and FcRn receptors based on surface plasmon resonance measurements.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhou et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522bdf https://doi.org/10.1158/1535-7163.27036028.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Fig.S9 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024
2Supplementary Fig.S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024
3Supplementary Fig.S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024
4Supplementary Fig.S3 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024
5Supplementary Fig.S3 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024

More related papers

Supplementary Fig.S4 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024
Supplementary Fig.S4 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024
Supplementary Fig.S5 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024